HDAC6 Inhibitors Sensitize Resistant T(11;14) Multiple Myeloma Cells to a Combination of Bortezomib and BH3 Mimetics

Overview

Journal Haematologica

Specialty Hematology

Date 2024 Oct 10

PMID 39385739

Authors

Cristina Florean

Manon Lernoux

Anne Lorant

Helene Losson

Guy Bormans

Michael Schnekenburger

Marc Diederich

Affiliations

Soon will be listed here.

References

Bhalla S, Melnekoff D, Aleman A, Leshchenko V, Restrepo P, Keats J . Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. Sci Adv. 2021; 7(47):eabg9551. PMC: 8598000. DOI: 10.1126/sciadv.abg9551. View

Butler K, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski A . Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc. 2010; 132(31):10842-6. PMC: 2916045. DOI: 10.1021/ja102758v. View

Imai Y, Hirano M, Kobayashi M, Futami M, Tojo A . HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action. Cancers (Basel). 2019; 11(4). PMC: 6520917. DOI: 10.3390/cancers11040475. View

Yee A, Raje N . Panobinostat and Multiple Myeloma in 2018. Oncologist. 2018; 23(5):516-517. PMC: 5947458. DOI: 10.1634/theoncologist.2017-0644. View

Mitsiades C, Mitsiades N, McMullan C, Poulaki V, Shringarpure R, Hideshima T . Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. 2003; 101(2):540-5. PMC: 327183. DOI: 10.1073/pnas.2536759100. View

Zeleke T, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H . Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nat Cancer. 2022; 4(2):257-275. PMC: 9992270. DOI: 10.1038/s43018-022-00489-5. View

Zhou X, Rasche L, Kortum K, Mersi J, Einsele H . BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica. 2022; 108(4):958-968. PMC: 10071122. DOI: 10.3324/haematol.2020.266841. View

Lernoux M, Schnekenburger M, Dicato M, Diederich M . Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors. Biochem Pharmacol. 2021; 188:114526. DOI: 10.1016/j.bcp.2021.114526. View

Vogl D, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R . Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2017; 23(13):3307-3315. PMC: 5496796. DOI: 10.1158/1078-0432.CCR-16-2526. View

10.

Ramkumar P, Abarientos A, Tian R, Seyler M, Leong J, Chen M . CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood Adv. 2020; 4(13):2899-2911. PMC: 7362346. DOI: 10.1182/bloodadvances.2019001346. View

11.

Monteith B, Sandhu I, Lee A . Management of Multiple Myeloma: A Review for General Practitioners in Oncology. Curr Oncol. 2023; 30(5):4382-4401. PMC: 10217377. DOI: 10.3390/curroncol30050334. View

12.

Shultz M, Cao X, Chen C, Cho Y, Davis N, Eckman J . Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. J Med Chem. 2011; 54(13):4752-72. DOI: 10.1021/jm200388e. View

13.

Jaenicke L, von Eyss B, Carstensen A, Wolf E, Xu W, Greifenberg A . Ubiquitin-Dependent Turnover of MYC Antagonizes MYC/PAF1C Complex Accumulation to Drive Transcriptional Elongation. Mol Cell. 2015; 61(1):54-67. DOI: 10.1016/j.molcel.2015.11.007. View

14.

Ziccheddu B, Da Via M, Lionetti M, Maeda A, Morlupi S, Dugo M . Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma. Clin Cancer Res. 2021; 27(23):6479-6490. PMC: 7612071. DOI: 10.1158/1078-0432.CCR-20-4366. View